In Brief: Visx/Laser Vision Centers
This article was originally published in The Gray Sheet
Visx/Laser Vision Centers: Sign purchasing contract under which LVC agrees to buy 20 Visx Star ophthalmic excimer laser systems "subject to Visx' production schedule," LVC states. The deal, which includes an option to purchase up to 20 additional units over the next year, would be worth "over $20 mil." if fully exercised, according to LVC. The Visx laser is approved for phototherapeutic keratectomy; on Oct. 20 the device received a conditional approval recommendation from FDA's Ophthalmic Devices Advisory Panel for use in photorefractive keratectomy ("The Gray Sheet" Oct. 23, I&W-21)...
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.